Axillary Lymph Node Dissection for Sentinel Lymph Node Micrometastases May Be Safely Omitted in Early-stage Breast Cancer Patients: Long-term Outcomes of a Prospective Study

Overview

Journal Indian J Surg Oncol

Specialty Oncology

Date 2012 Aug 30

PMID 22930620

Authors

Igor Langer

Ulrich Guller

Carsten T Viehl

Holger Moch

Edward Wight

Felix Harder

Daniel Oertli

Markus Zuber

Affiliations

Soon will be listed here.

Abstract

Objectives: To evaluate the long-term disease-free and overall survival of patients with sentinel lymph node (SLN) micrometastases, in whom a completion axillary lymph node dissection (ALND) was systematically omitted.

Background: The use of step sectioning and immunohistochemistry for SLN analysis results in a more accurate histopathologic examination and a higher detection rate of micrometastases. However, the clinical relevance and therapeutic implications of SLN micrometastases remain a matter of debate.

Methods: In this prospective study, 236 SLN biopsies were performed in 234 consecutive early-stage breast cancer patients (T1, T2 ≤ 3 cm, cN0 M0) between 1998 and 2002. The SLN were examined by step sectioning and stained with hematoxylin and eosin and immunohistochemistry. None of the patients with negative SLN or SLN micrometastases (International Union Against Cancer classification, >0.2 to ≤ 2 mm) underwent a completion ALND or radiation to the axilla. Long-term overall and disease-free survivals were compared between patients with negative SLN and those with SLN micrometastases by log rank tests.

Results: The SLN was negative in 55% of patients (123 of 224). SLN micrometastases were detected in 27 patients (27 of 224, 12%). After a median followup of 77 months (range, 24-106 months), neither locoregional recurrences nor distant metastases occurred in any of the 27 patients with SLN micrometastases. There were no statistically significant differences for overall (P = 0.656), locoregional (P = 0.174), and axillary and distant disease-free survival (P = 0.15) between patients with negative SLN and SLN micrometastases.

Conclusions: This analysis of unselected patients provides evidence that a completion level I and II ALND may be safely omitted in early-stage breast cancer patients with SLN micrometastases.

References

Weaver D, Krag D, Ashikaga T, Harlow S, OConnell M . Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer. 2000; 88(5):1099-107. View

Haid A, Knauer M, Koberle-Wuhrer R, Ammann K, Koller L, Eiter H . Medium-term follow-up data after sentinel node biopsy alone for breast cancer. Eur J Surg Oncol. 2006; 32(10):1180-5. DOI: 10.1016/j.ejso.2006.04.010. View

Chagpar A, Middleton L, Sahin A, Meric-Bernstam F, Kuerer H, Feig B . Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005; 103(8):1581-6. DOI: 10.1002/cncr.20934. View

Langer I, Guller U, Berclaz G, Koechli O, Schaer G, Fehr M . Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg. 2007; 245(3):452-61. PMC: 1877006. DOI: 10.1097/01.sla.0000245472.47748.ec. View

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S . Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst. 1999; 91(4):368-73. DOI: 10.1093/jnci/91.4.368. View

Fournier K, Schiller A, Perry R, Laronga C . Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection. Ann Surg. 2004; 239(6):859-63. PMC: 1356294. DOI: 10.1097/01.sla.0000128302.05898.a7. View

Shivers S, Cox C, Leight G, Beauchamp D, Blumencranz P, Ross M . Final results of the Department of Defense multicenter breast lymphatic mapping trial. Ann Surg Oncol. 2002; 9(3):248-55. DOI: 10.1007/BF02573062. View

Viale G, Maiorano E, Pruneri G, Mastropasqua M, Valentini S, Galimberti V . Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg. 2005; 241(2):319-25. PMC: 1356918. DOI: 10.1097/01.sla.0000150255.30665.52. View

10.

Cody 3rd H, Hill A, Tran K, Brennan M, Borgen P . Credentialing for breast lymphatic mapping: how many cases are enough?. Ann Surg. 1999; 229(5):723-6; discussion 726-8. PMC: 1420817. DOI: 10.1097/00000658-199905000-00015. View

11.

Tafra L, LANNIN D, Swanson M, Van Eyk JJ , Verbanac K, Chua A . Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg. 2001; 233(1):51-9. PMC: 1421166. DOI: 10.1097/00000658-200101000-00009. View

12.

van der Ploeg I, Nieweg O, van Rijk M, Valdes Olmos R, Kroon B . Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008; 34(12):1277-84. DOI: 10.1016/j.ejso.2008.01.034. View

13.

Jeruss J, Sener S, Brinkmann E, Bilimoria M, Barrera Jr E, Alwawi E . Axillary recurrence after sentinel node biopsy. Ann Surg Oncol. 2005; 12(1):34-40. DOI: 10.1007/s10434-004-1164-2. View

14.

Cote R, Peterson H, Chaiwun B, Gelber R, Goldhirsch A, Castiglione-Gertsch M . Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet. 1999; 354(9182):896-900. DOI: 10.1016/s0140-6736(98)11104-2. View

15.

Chu K, Turner R, Hansen N, Brennan M, Giuliano A . Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis. Ann Surg Oncol. 2000; 6(8):756-61. DOI: 10.1007/s10434-999-0756-2. View

16.

Hwang R, Gonzalez-Angulo A, Yi M, Buchholz T, Meric-Bernstam F, Kuerer H . Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007; 110(4):723-30. DOI: 10.1002/cncr.22847. View

17.

Martin 2nd R, Chagpar A, Scoggins C, Edwards M, Hagendoorn L, Stromberg A . Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer. Ann Surg. 2005; 241(6):1005-12. PMC: 1359077. DOI: 10.1097/01.sla.0000165200.32722.02. View

18.

Hill A, Tran K, Akhurst T, Yeung H, Yeh S, Rosen P . Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg. 1999; 229(4):528-35. PMC: 1191739. DOI: 10.1097/00000658-199904000-00012. View

19.

. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) Breast Cancer Study Group. Lancet. 1990; 335(8705):1565-8. View

20.

Mansel R, Fallowfield L, Kissin M, Goyal A, Newcombe R, Dixon J . Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006; 98(9):599-609. DOI: 10.1093/jnci/djj158. View